New pill shows promise for rare joint tumor in early trial

NCT ID NCT07499362

Recruiting now Disease control Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 11, 2026 · Updated 4 times

Summary

This phase 2 trial tests a daily oral drug called pimicotinib in 20 Japanese adults with tenosynovial giant cell tumor (TGCT) that cannot be removed by surgery. The study aims to see if the drug is safe, how it moves through the body, and whether it shrinks tumors. Participants take the drug in 28-day cycles until their disease worsens or side effects become unacceptable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pimicotinib (a drug taken by mouth once daily)
What this could lead to: If successful, this could provide a new treatment option for people with TGCT that cannot be surgically removed, potentially shrinking tumors and easing symptoms.
What could go wrong: This is a small, early-phase study (20 participants) with no placebo group. It only tests one dose and focuses on Japanese patients, so results may not apply broadly. Side effects and lack of efficacy are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TENOSYNOVIAL GIANT CELL TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Giant Cell Tumor of Tendon Sheath tenosynovial giant cell tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TENOSYNOVIAL GIANT CELL TUMOR

Contacts and locations

Locations

Kyushu University Hospital - 300173484
RECRUITING

Fukuoka, Japan
Nagoya University Hospital - 300176284
RECRUITING

Nagoya, Japan
National Cancer Center Hospital
RECRUITING

Chūōku, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.